A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDXG SEC filings page.
MiMedx Group, Inc (MDXG) reported $303.7M in revenue over the twelve months to Sep 30, 2026, down 22.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MiMedx is scaling profitably, but its latest growth produced less incremental operating profit while receivables expanded faster than sales.
The business gained efficiency between FY2023 and FY2025: revenue increased30.2% while operating income increased72.1% . In FY2025, however, revenue grew20.0% while operating income grew8.5% , so the latest expansion produced less incremental operating profit than the preceding two-year stretch.
Operating cash flow reached
Debt-to-equity fell from 0.3x in FY2023 to 0.1x in FY2025, reducing reliance on borrowing as the balance sheet expanded. Liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of MiMedx Group, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. MiMedx Group, Inc scores 60/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. MiMedx Group, Inc scores 73/100 on it among other operating companies.
MiMedx Group, Inc held more cash than long-term debt at the end of fiscal year 2025, with $166.1M of cash against $16.5M of long-term debt. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and MiMedx Group, Inc scores 94/100 among other operating companies measured the same way.
MiMedx Group, Inc held $4.32 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 4.32. Liquidity ranks operating companies on that ratio, and MiMedx Group, Inc scores 89/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. MiMedx Group, Inc scores 58/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. MiMedx Group, Inc scores 71/100 on it among other operating companies.
MiMedx Group, Inc scores 5.51, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $445.1M against total liabilities of $86.1M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
MiMedx Group, Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, MiMedx Group, Inc generates $1.52 in operating cash flow ($74.0M OCF vs $48.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
MiMedx Group, Inc earns $35.83 in operating income for every $1 of interest expense ($63.9M vs $1.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
MiMedx Group, Inc generated $62.3M in revenue in Q3 2026. This represents a decrease of 45.2% from the same quarter a year earlier. Against the prior quarter it is down 3.2%.
MiMedx Group, Inc's EBITDA was -$11.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 148.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
MiMedx Group, Inc reported a net loss of $8.7M in Q3 2026. This represents a decrease of 151.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
MiMedx Group, Inc earned -$0.06 per diluted share (EPS) in Q3 2026. This represents a decrease of 154.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
MiMedx Group, Inc held $120.8M in cash against $0 in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
MiMedx Group, Inc's gross margin was 79.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.8 percentage points.
MiMedx Group, Inc's operating margin was -18.8% in Q3 2026, reflecting core business profitability. This is down 38.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.9 percentage points.
MiMedx Group, Inc's net profit margin was -13.9% in Q3 2026, showing the share of revenue converted to profit. This is down 28.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.1 percentage points.
MiMedx Group, Inc's quarterly ROE was -4.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 11.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.8 percentage points.
Capital Allocation
MiMedx Group, Inc invested $2.8M in research and development in Q3 2026. This represents a decrease of 24.5% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.
MiMedx Group, Inc spent $304K on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q3 2026.
MDXG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.3M-45.2% | $64.4M-34.7% | $59.0M-33.1% | $118.1M+27.1% | $113.7M+35.3% | $98.6M+13.1% | $88.2M+4.1% | $92.9M+7.0% |
| Cost of Revenue | $12.6M-32.8% | $20.0M+7.0% | $17.4M+4.9% | $19.1M+12.7% | $18.7M+22.2% | $18.7M+25.8% | $16.6M+27.5% | $16.9M+22.2% |
| Gross Profit | $49.7M-47.7% | $44.4M-44.5% | $41.6M-41.9% | $99.0M+30.3% | $95.0M+38.2% | $79.9M+10.5% | $71.6M-0.1% | $76.0M+4.1% |
| R&D Expenses | $2.8M-24.5% | $2.8M-15.9% | $4.1M+24.4% | $4.8M+33.4% | $3.7M+26.9% | $3.3M+9.7% | $3.3M+17.1% | $3.6M+46.7% |
| SG&A Expenses | $58.3M-15.5% | $59.8M-6.8% | $53.2M-11.2% | $73.1M+19.7% | $69.0M+28.9% | $64.2M+15.8% | $60.0M+8.8% | $61.0M+12.3% |
| Operating Income | -$11.7M-152.7% | -$18.5M-249.3% | -$16.0M-294.5% | $21.1M+90.6% | $22.2M+98.8% | $12.4M-47.2% | $8.3M-37.5% | $11.1M-28.6% |
| EBITDA | -$11.0M-148.3% | -$17.7M-236.1% | -$15.2M-270.9% | $21.8M+84.4% | $22.9M+91.7% | $13.0M-46.2% | $8.9M-36.1% | $11.8M-27.5% |
| Interest Expense | N/A | N/A | $402K-15.9% | $405K-22.3% | $425K-18.4% | $475K-9.0% | $478K-79.9% | $521K |
| Income Tax | -$2.4M-139.0% | -$2.9M-186.8% | -$4.5M-381.4% | $6.6M+73.3% | $6.1M+72.3% | $3.4M-39.4% | $1.6M-32.3% | $3.8Mn/m |
| Net Income | -$8.7M-151.8% | -$14.8M-254.3% | -$10.9M-254.6% | $15.2M+104.2% | $16.7M+106.9% | $9.6M-45.4% | $7.0M-24.2% | $7.4M-86.1% |
| EPS (Basic) | -$0.06-154.5% | -$0.10-242.9% | -$0.07-240.0% | $0.10+100.0% | $0.11+120.0% | $0.07-41.7% | $0.05-16.7% | $0.05-87.5% |
| EPS (Diluted) | -$0.06-154.5% | -$0.10-266.7% | -$0.07-240.0% | $0.10+100.0% | $0.11+120.0% | $0.06-50.0% | $0.05-16.7% | $0.05-86.5% |
| Diluted Shares (Avg) | 146M-2.6% | 148M-1.0% | 148M-0.8% | N/A | 150M+0.9% | 149M+0.3% | 150M-0.2% | N/A |
MDXG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $264.6M-17.1% | $281.0M-3.5% | $308.7M+14.1% | $342.7M+29.8% | $319.0M+30.8% | $291.1M+26.5% | $270.4M+22.0% | $263.9M+10.4% |
| Current Assets | $187.2M-26.3% | $205.4M-7.0% | $240.3M+20.1% | $277.5M+44.6% | $254.1M+47.6% | $220.9M+43.4% | $200.1M+44.1% | $191.9M+16.8% |
| Cash & Equivalents | $120.8M-15.0% | $135.8M+14.3% | $159.8M+50.1% | $166.1M+59.1% | $142.1M+60.0% | $118.9M+72.2% | $106.4M+119.5% | $104.4M+27.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $22.1M-16.7% | $20.9M-15.9% | $26.2M+9.0% | $25.3M+6.4% | $26.5M+9.3% | $24.9M-0.7% | $24.1M-1.6% | $23.8M+13.3% |
| Accounts Receivable | $37.3M-52.3% | $41.3M-40.3% | $46.0M-26.1% | $75.7M+35.6% | $78.2M+44.7% | $69.2M+31.1% | $62.3M+9.2% | $55.8M+3.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% |
| Total Liabilities | $53.5M-33.2% | $65.0M-12.7% | $65.7M-2.8% | $86.1M+21.6% | $80.0M+27.3% | $74.5M+19.9% | $67.6M+2.6% | $70.8M-26.5% |
| Current Liabilities | $43.0M-25.4% | $38.5M-23.4% | $44.5M+4.5% | $64.3M+40.9% | $57.7M+37.5% | $50.3M+25.7% | $42.6M+0.9% | $45.6M-0.9% |
| Non-Current Liabilities | $10.4M-53.3% | $26.5M+9.5% | $21.2M-15.3% | $21.8M-13.4% | $22.4M+6.8% | $24.2M+9.3% | $25.0M+5.5% | $25.2M-49.9% |
| Long-Term Debt | $0-100.0% | $15.7M-8.7% | $16.1M-8.2% | $16.5M-7.6% | $16.8M-6.5% | $17.2M-5.7% | $17.5M-5.0% | $17.8M-62.9% |
| Total Equity | $211.1M-11.7% | $216.0M-0.3% | $242.9M+19.8% | $256.5M+32.9% | $238.9M+32.0% | $216.6M+28.9% | $202.8M+30.2% | $193.1M+35.3% |
| Retained Earnings | -$77.1Mn/m | -$68.4Mn/m | -$53.5Mn/m | -$42.7Mn/m | -$57.9Mn/m | -$74.6Mn/m | -$84.2Mn/m | -$91.3Mn/m |
MDXG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.9M-86.6% | -$10.0M-169.5% | $1.9M-64.5% | $25.0M+32.9% | $29.3M+49.5% | $14.4M-33.9% | $5.3M-11.4% | $18.8M+83.1% |
| Depreciation & Amortization | $665K-2.8% | $732K+11.2% | $829K+26.2% | $701K-7.4% | $684K-11.4% | $658K-12.0% | $657K-12.0% | $757K-5.7% |
| Stock-Based Compensation | N/A | N/A | -$1.7M-139.8% | N/A | N/A | N/A | $4.3M-1.8% | N/A |
| Investing Cash Flow | -$193Kn/m | -$635Kn/m | -$5.6Mn/m | -$335Kn/m | -$5.3M-4753.1% | -$887Kn/m | -$406Kn/m | -$2.8Mn/m |
| Financing Cash Flow | -$18.8Mn/m | -$13.3Mn/m | -$2.6Mn/m | -$583Kn/m | -$857K-3274.1% | -$1.1Mn/m | -$2.9Mn/m | -$400Kn/m |
| Share Buybacks | $304Kn/m | N/A | N/A | $0 | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
MDXG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.8%-3.7pp | 69.0%-12.1pp | 70.6%-10.7pp | 83.9%+2.1pp | 83.5%+1.8pp | 81.0%-1.9pp | 81.2%-3.4pp | 81.8%-2.3pp |
| Operating Margin | -18.8%-38.3pp | -28.7%-41.2pp | -27.2%-36.6pp | 17.8%+5.9pp | 19.5%+6.2pp | 12.6%-14.3pp | 9.3%-6.2pp | 11.9%-5.9pp |
| Net Margin | -13.9%-28.7pp | -23.1%-32.8pp | -18.4%-26.4pp | 12.9%+4.8pp | 14.7%+5.1pp | 9.8%-10.5pp | 8.0%-3.0pp | 8.0%-53.6pp |
| Return on Equity | -4.1%-11.1pp | -6.9%-11.3pp | -4.5%-7.9pp | 5.9%+2.1pp | 7.0%+2.5pp | 4.4%-6.0pp | 3.5%-2.5pp | 3.9%-33.6pp |
| Return on Assets | -3.3%-8.5pp | -5.3%-8.6pp | -3.5%-6.1pp | 4.4%+1.6pp | 5.3%+1.9pp | 3.3%-4.4pp | 2.6%-1.6pp | 2.8%-19.6pp |
| Current Ratio | 4.35-0.1x | 5.33+0.9x | 5.39+0.7x | 4.32+0.1x | 4.41+0.3x | 4.39+0.5x | 4.70+1.4x | 4.21+0.6x |
| Debt-to-Equity | 0.00-0.1x | 0.070.0x | 0.070.0x | 0.060.0x | 0.070.0x | 0.080.0x | 0.090.0x | 0.09-0.2x |
| Liabilities-to-Equity | 0.25-0.1x | 0.300.0x | 0.27-0.1x | 0.340.0x | 0.340.0x | 0.340.0x | 0.33-0.1x | 0.37-0.3x |
| Asset Turnover | 0.24-0.1x | 0.23-0.1x | 0.19-0.1x | 0.340.0x | 0.360.0x | 0.340.0x | 0.33-0.1x | 0.350.0x |
Not reported in any period shown, so not listed: FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| MiMedx Group, Inc MDXG | FY2025 | $418.6M | $48.6M | 11.6% | $445.1M | 74/100 |
| Monopar Therapeutics Inc. MNPR | FY2025 | $0 | -$13.7M | N/A | $467.6M | — |
| Shattuck Labs, Inc. STTK | FY2025 | $1.0M | -$48.8M | N/A | $454.2M | 61/100 |
| Sana Biotechnology, Inc. SANA | FY2025 | N/A | -$244.2M | N/A | $476.4M | — |
| Neurogene, Inc. NGNE | FY2025 | $0 | -$90.4M | N/A | $458.5M | — |
| Assembly Biosciences, Inc ASMB | FY2025 | $72.3M | -$6.1M | -8.5% | $454.4M | 87/100 |
Where MiMedx Group, Inc Ranks
Frequently Asked Questions
MiMedx Group, Inc (MDXG) reported $418.6M in total revenue for fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
MiMedx Group, Inc (MDXG) revenue grew by 20.0% year-over-year, from $348.9M to $418.6M in fiscal year 2025.
No, MiMedx Group, Inc (MDXG) reported a net loss of $19.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $48.6M, with a net profit margin of 11.6%.
MiMedx Group, Inc (MDXG) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, MiMedx Group, Inc (MDXG) had $166.1M in cash and equivalents against $16.5M in long-term debt.
MiMedx Group, Inc (MDXG) had a gross margin of 82.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
MiMedx Group, Inc (MDXG) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
MiMedx Group, Inc (MDXG) had a net profit margin of 11.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
MiMedx Group, Inc (MDXG) has a return on equity of 18.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
MiMedx Group, Inc (MDXG) generated $74.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
MiMedx Group, Inc (MDXG) had $342.7M in total assets as of fiscal year 2025, including both current and long-term assets.
MiMedx Group, Inc (MDXG) invested $15.1M in research and development during fiscal year 2025.
MiMedx Group, Inc (MDXG) had a current ratio of 4.32 as of fiscal year 2025, which is generally considered healthy.
MiMedx Group, Inc (MDXG) had a debt-to-equity ratio of 0.06 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
MiMedx Group, Inc (MDXG) had a liabilities-to-equity ratio of 0.34 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
MiMedx Group, Inc (MDXG) had a return on assets of 14.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
MiMedx Group, Inc (MDXG) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $445.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
MiMedx Group, Inc (MDXG) trades at 1.5x sales, its market capitalization divided by $303.7M revenue, trailing 12 months to September 30, 2026. The market capitalization is $445.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
MiMedx Group, Inc (MDXG) has an Altman Z-Score of 5.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
MiMedx Group, Inc (MDXG) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
MiMedx Group, Inc (MDXG) has an earnings quality ratio of 1.52x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
MiMedx Group, Inc (MDXG) has an interest coverage ratio of 35.83x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
MiMedx Group, Inc (MDXG) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.